Please assess the completion status of the following clinical trial:

Trial Title: Lymphedema Study for Arm or Leg Lymphedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* a history of lymphedema of one or more limbs (unilateral or bilateral), with a duration of \> 6 months.~Exclusion Criteria:~* Patients with active cancer, infection or bleeding tendency will be excluded.~* We will also exclude patients with medical contraindications to NSAIDs, including history of allergies, know gastrointestinal intolerance, or other serious systemic illness (e.g., renal failure, hepatic dysfunction, congestive heart failure, neurological or psychological impairment) that would impair the patients' ability to participate.~* Minors (\<18 years of age) \*\>90 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Part 1: Exploratory Group (Type: EXPERIMENTAL): Ketoprofen 225-300 mgs daily, taken orally~Ketoprofen-exploratory group: 225-300 mgs daily for four to six months
- Part 2: Open-label Group (Type: EXPERIMENTAL): Ketoprofen 225 mg daily, taken orally~Open-label group: 75 mgs, three times daily, for four months
- Part 3: Placebo Group (Type: PLACEBO_COMPARATOR): Participants randomized to receive placebo: placebo, three times daily, taken orally~Placebo: 1 capsule, three times daily, for four months
- Part 3: Ketoprofen Group (Type: ACTIVE_COMPARATOR): Participants randomized to receive active medication: ketoprofen 75 mgs., three times daily, taken orally~Ketoprofen: 1 capsule, three times daily, for four months

Based on this trial design, predict the completion outcome and termination type (if applicable).